Spruce Biosciences, Inc SPRB
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-09 |
| Shares Out. | 2,750,000 |
| Website | sprucebio.com/ ↗ |
| Phone | 13026365400 |
| Employees | 8 |
| Net Income | -$12.3M |
| Free Cash Flow | -$29.3M |
| Total Assets | $56.2M |
| Total Liabilities | $21.5M |
| Equity | $34.6M |
About Spruce Biosciences, Inc
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
Spruce Biosciences, Inc is a publicly traded company under the ticker symbol SPRB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)